|
Rinvoq goes for psoriatic arthritis approval
|
Thu-16-12-2021, 13:44 PM
Update: AbbVie today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
|
|
« Next Oldest | Next Newest »
|
| Possibly Related Threads… | |||||
| Thread | Author | Replies | Views | Last Post | |
|
Bimzelx vs Skyrizi study for psoriatic arthritis | Fred | 0 | 512 |
Mon-30-09-2024, 14:22 PM Last Post: Fred |
|
|
FDA declines the approval of Duobrii for psoriasis | Fred | 1 | 2,738 |
Mon-27-05-2024, 21:06 PM Last Post: Trampledrosie |
|
|
Bimzelx gets recommendation for psoriatic arthritis in the EU | Fred | 2 | 2,656 |
Sat-10-06-2023, 14:33 PM Last Post: Forest Walker |
|
|
Tremfya for psoriatic arthritis phase 3b data | Fred | 0 | 1,486 |
Wed-31-05-2023, 16:26 PM Last Post: Fred |
|
|
Bimzelx and psoriatic arthritis long term data | Fred | 0 | 1,578 |
Wed-31-05-2023, 14:00 PM Last Post: Fred |
Health Boards
